Overview

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

Status:
Completed

Trial end date:
2020-09-14

Target enrollment:
0

Participant gender:
All

Summary

Diagnostic determination of disease and treatment responses has been limited to qualitative imaging, measurement of serum markers of disease, and sampling of tissue. In each of these instances, there is a built in error either due to sensitivity and specificity issues, clinician interpretation of results, or acceptance of the use of an indirect marker (blood test) of what is happening elsewhere in the body - at the tissue level. The Fleming Method for Tissue and Vascular Differentiation and Metabolism (FMTVDM) using same state single or sequential quantification comparisons [1] provides the first and only patented test (#9566037) - along with the associated submitted patent applications ruled to be covered under #9566037 - that quantitatively measures changes in tissue resulting from inter alia a disease process. This includes inter alia coronary artery disease (CAD), cancer and infectious/inflammatory processes including CoVid-19 pneumonia (CVP) resulting from the metabolic and regional blood flow differences (RBFDs) caused by these diseases. The purpose of this paper is to make clinicians and researchers aware of this proposed method for investigating the prevalence and severity of CVP - in addition to providing rapid determination of treatment response in each patient, directing treatment decisions; thereby reducing the loss of time, money, resources and patient lives.

Phase:

Phase 2/Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

The Camelot Foundation

Treatments:

Azithromycin
Clindamycin
Clindamycin palmitate
Clindamycin phosphate
Doxycycline
Hydroxychloroquine
Interferon alpha-2
Interferon-alpha
Interferons
Losartan
Methylprednisolone
Primaquine
Remdesivir

Criteria

Inclusion Criteria: CoVid-19 -

Exclusion Criteria: Decision by patient to not participate.

-